A Phase 4 interventional study of IV morphine sulfate or Sponsor-approved equivalent and EXPAREL in Bowel Obstruction, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-14.
Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Intestinal Obstruction with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Intestinal Obstruction · United States.
Among the 29 studies in Intestinal Obstruction with a site in United States, this one is the 4th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 4, and was the 12th registered.
105 studies on the registry are indexed under Intestinal Obstruction; 16 are open to participants now.
Browse Intestinal Obstruction studies →2 of the 29 studies in Intestinal Obstruction with a site in United States are open now. Recruiting first, the newest first:
GT Metabolic Solutions, Inc. · Sites in United States
Ages 22+
Seattle Children's Hospital · Sites in United States
Ages 0 days–55 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 6 Intestinal Obstruction studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 1 · Phase 4 5
First in 1998; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 122 is above the median of 64 across 55 interventional studies indexed under Intestinal Obstruction.
Median enrollment 59 across the 16 interventional studies, 107 across the 8 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pacira Pharmaceuticals, Inc, one of the names counted as Pacira BioSciences, Inc.. Under that name alone:
Pacira Pharmaceuticals, Inc is the lead sponsor of 102 studies on the registry; 3 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 17 (65%) have results posted.
Pacira BioSciences, Inc. has 4 studies filed under Intestinal Obstruction — fewer than ten, so there is no comparison to draw.
2 of the studies in Intestinal Obstruction with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06928545GT Metabolic Solutions, Inc.MagDI U.S. Registry | 2027-03 |
| NCT06072976Seattle Children's HospitalThe Influence of Feeding Source on the Gut Microbiome and Time to Full Feeds in Neonates With Congenital Gastrointestinal Pathologies | 2027-06-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 29 studies in Intestinal Obstruction with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospital costs.
This is a Phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome injectable suspension) compared with postsurgical administration of standardized intravenous (IV) morphine sulfate or Sponsor-approved equivalent for postsurgical analgesia in adult patients undergoing laparoscopic colectomy with general anesthesia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
In addition, a patient was ineligible if he or she met the following criteria during surgery:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Standard of Care (SOC)
Drug: IV morphine sulfate or Sponsor-approved equivalent
EXPAREL (bupivacaine liposome injectable suspension)
Drug: EXPAREL
Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care. All patients will be offered rescue analgesia, as needed.
Also known as: bupivacaine liposome injectable suspension
Total Opioid Burden
Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Health Economic Benefits - Total Cost of Hospitalization
Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever was sooner.
Time frame: Wound closure to time hospital discharge order is written or Day 30, whichever is sooner.
Health Economic Benefits - Length of Stay (LOS)
Length of stay, recorded in days, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.
Time frame: Wound closure at time hospital discharge order is written or Day 30, whichever is sooner
Incidence of Opioid-related Adverse Events
Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.
Time frame: Wound closure at time hospital discharge order is written or Day 30, whichever is sooner.
Patient Satisfaction With Pain Treatment After Surgery
Responses to question pertaining to patient satisfaction with pain treatment
Time frame: Wound closure at time hospital discharge order is written or Day 30, whichever is sooner.
| Milestone | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Started | 77 | 45 |
| Completed | 66 | 36 |
| Not completed | 11 | 9 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Didn't meet intraoperative criteria | 8 | 7 |
| Withdrew: Withdrawal by subject | 0 | 1 |
Total opioid consumed (IV and PO) postsurgically until hospital discharge order is written or through Day 30, whichever is sooner.
| mg | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Total Opioid Burden | 96.47 ± 77.74 | 32.06 ± 53.16 |
Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever was sooner.
| dollars | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Health Economic Benefits - Total Cost of Hospitalization | 15158.79 ± 11417.50 | 14802.70 ± 18382.12 |
Length of stay, recorded in days, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.
| days | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Health Economic Benefits - Length of Stay (LOS) | 4.0 (0 to 30) | 3.0 (1.9 to 10.7) |
Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus.
| participants | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Incidence of Opioid-related Adverse Events | 23 | 2 |
Responses to question pertaining to patient satisfaction with pain treatment
| participants | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Extremely Satisfied | 30 | 17 |
| Satisfied | 19 | 5 |
| Neither Satisfied nor Dissatisfied | 0 | 2 |
| Dissatisfied | 3 | 0 |
| Extremely Dissatisfied | 1 | 0 |
| Not Reported | 3 | 2 |
Collected over Through Day 30 post surgery.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IV Morphine Sulfate or Sponsor-approved Equivalent | — | 9/67 (13.4%) | 53/67 (79.1%) |
| EXPAREL | — | 5/38 (13.2%) | 15/38 (39.5%) |
| Event | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| Small Intestinal ObstructionGastrointestinal disorders | 2/67 | 0/38 |
| Urinary Tract InfectionInfections and infestations | 2/67 | 0/38 |
| Abdominal painGastrointestinal disorders | 1/67 | 1/38 |
| Gastrointestinal PerforationGastrointestinal disorders | 0/67 | 1/38 |
| Intestinal PerforationGastrointestinal disorders | 0/67 | 1/38 |
| Cholecystitis AcuteHepatobiliary disorders | 0/67 | 1/38 |
| AbscessInfections and infestations | 0/67 | 1/38 |
| Bacterial InfectionInfections and infestations | 0/67 | 1/38 |
| Bacterial SepsisInfections and infestations | 0/67 | 1/38 |
| Wound InfectionInfections and infestations | 0/67 | 1/38 |
| Event | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL |
|---|---|---|
| NauseaGastrointestinal disorders | 23/67 | 3/38 |
| HeadacheNervous system disorders | 7/67 | 0/38 |
| Abdominal DistentionGastrointestinal disorders | 5/67 | 0/38 |
| Abdominal PainGastrointestinal disorders | 5/67 | 2/38 |
| VomitingGastrointestinal disorders | 5/67 | 0/38 |
| Urinary RetentionRenal and urinary disorders | 5/67 | 0/38 |
| PruritusSkin and subcutaneous tissue disorders | 5/67 | 0/38 |
| AnemiaBlood and lymphatic system disorders | 4/67 | 2/38 |
| LeukocytosisBlood and lymphatic system disorders | 4/67 | 0/38 |
| Urinary Tract InfectionInfections and infestations | 4/67 | 0/38 |
122 subjects were enrolled. Of these, 105 subjects received study drug: 67 subjects received IV morphine sulfate or sponsor-approved equivalent and 38 subjects received EXPAREL.
| Age, Continuous(years) | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL | Total |
|---|---|---|---|
| Mean | 58.6 ± 14.35 | 57.8 ± 11.86 | 58.3 ± 13.45 |
| Sex: Female, Male(Participants) | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL | Total |
|---|---|---|---|
| Female | 35 | 21 | 56 |
| Male | 32 | 17 | 49 |
| Race/Ethnicity, Customized(participants) | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL | Total |
|---|---|---|---|
| Hispanic or Latino | 7 | 4 | 11 |
| Not Hispanic or Latino | 60 | 34 | 94 |
| American Society of Anesthesiologist (ASA) Classification(participants) | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL | Total |
|---|---|---|---|
| Normal [1] | 1 | 0 | 1 |
| Mild Systemic Disease [2] | 32 | 25 | 57 |
| Severe Systemic Disease [3] | 32 | 13 | 45 |
| Severe Systemic Disease Threat to Life [4] | 2 | 0 | 2 |
| Patient's Pain Level 24 Hours Prior to Surgery(units on a scale) | IV Morphine Sulfate or Sponsor-approved Equivalent | EXPAREL | Total |
|---|---|---|---|
| Mean | 1.9 ± 2.14 | 1.3 ± 0.86 | 1.7 ± 1.81 |
The record gives a start of Dec 2011, a primary completion of Sep 2012 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal Bupivacaine